DKK1 and Miyoshi myopathy: The latter view is in line with a large body of clinical evidence on neoplasms constitutively expressing Dkk1 (MM, prostate carcinoma), showing that, on balance, this canonical Wnt inhibitor facilitates bone loss (osteolysis) in vivo.